MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
MIRA Pharmaceuticals (NASDAQ:MIRA) announced shareholder approval for its acquisition of SKNY Pharmaceuticals, valued at a combined enterprise value of over $60 million. The transaction includes SKNY contributing $5 million in assets or cash to MIRA.
The acquisition brings SKNY-1, a novel oral therapeutic candidate targeting obesity and smoking cessation, to MIRA's pipeline. Preclinical studies showed promising results with up to 30% body weight reduction and nicotine craving reversal. The drug's unique mechanism selectively targets CB1 and CB2 receptors and MAO-B, potentially offering improved safety compared to earlier treatments.
The combined company aims to address markets projected to reach $150 billion for obesity therapeutics by early 2030s and $50.9 billion for smoking cessation by 2030.
MIRA Pharmaceuticals (NASDAQ:MIRA) ha annunciato l'approvazione da parte degli azionisti per l'acquisizione di SKNY Pharmaceuticals, valutata con un valore d'impresa combinato superiore a $60 milioni. L'operazione prevede che SKNY contribuisca $5 milioni in asset o liquidità a MIRA.
L'acquisizione porta SKNY-1, un nuovo candidato terapeutico orale mirato all'obesità e al cessare il fumo, nel portafoglio di MIRA. Gli studi preclinici hanno mostrato risultati promettenti con una riduzione del peso corporeo fino al 30% e una reversal del desiderio di nicotina. Il meccanismo d'azione unico prende di mira selettivamente i recettori CB1 e CB2 e MAO-B, potenzialmente offrendo una maggiore sicurezza rispetto ai trattamenti precedenti.
L'azienda combinata intende rivolgersi a mercati stimati intorno a $150 miliardi per i trattamenti per l'obesità entro i primi anni del 2030 e $50,9 miliardi per l'uso nel cessare il fumo entro il 2030.
MIRA Pharmaceuticals (NASDAQ:MIRA) ha anunciado la aprobación de los accionistas para adquirir SKNY Pharmaceuticals, con un valor de empresa combinado superior a $60 millones. La operación incluye que SKNY aporte $5 millones en activos o efectivo a MIRA.
La adquisición incorpora SKNY-1, un candidato terapéutico oral novedoso que apunta a la obesidad y a la cesación del tabaquismo, al portafolio de MIRA. Los estudios preclínicos mostraron resultados prometedores con una reducción de peso corporal de hasta 30% y la reversión de la ansiedad por nicotina. El mecanismo único del fármaco apunta selectivamente a los receptores CB1 y CB2 y MAO-B, lo que podría ofrecer una mayor seguridad frente a tratamientos anteriores.
La empresa resultante espera abordar mercados estimados en $150 mil millones para terapéuticas de obesidad a principios de la década de 2030 y $50,9 mil millones para cesación del tabaquismo para 2030.
MIRA Pharmaceuticals (NASDAQ:MIRA)가 주주들의 승인을 받아 SKNY Pharmaceuticals를 인수했다고 발표했습니다. 합산 기업가치가 $60백만을 초과합니다. 거래에는 SKNY가 MIRA에 $5백만의 자산 또는 현금을 기여하는 것이 포함됩니다.
인수로 SKNY-1이 MIRA의 파이프라인에 추가됩니다. 이 신개발 경구 치료 candidates는 비만과 흡연 중단을 목표로 합니다. 전임상 연구에서 최대 30%의 체중 감소와 니코틴 갈망의 억제가 유망하게 나타났습니다. 이 약물의 독특한 작용 기전은 CB1 및 CB2 수용체와 MAO-B를 선택적으로 겨냥하며, 초기 치료보다 안전성이 개선될 가능성이 있습니다.
합병기업은 2030년대 초까지 $1500억의 비만 치료제 시장과 2030년까지 $509억의 흡연 중단 시장을 목표로 합니다.
MIRA Pharmaceuticals (NASDAQ:MIRA) a obtenu l'approbation des actionnaires pour l'acquisition de SKNY Pharmaceuticals, évaluée à une valeur d'entreprise combinée supérieure à $60 millions. La transaction prévoit que SKNY contribue $5 millions en actifs ou en liquidités à MIRA.
L'acquisition apporte SKNY-1, un candidat thérapeutique oral innovant ciblant l'obésité et l'arrêt du tabac, au portefeuille de MIRA. Les études précliniques ont montré des résultats prometteurs avec une réduction du poids corporel allant jusqu'à 30% et une inversion du craving nicotinique. Le mécanisme d'action unique cible sélectivement les récepteurs CB1 et CB2 et MAO-B, offrant potentiellement une meilleure sécurité que les traitements antérieurs.
L'entreprise fusionnée vise des marchés estimés à $150 milliards pour les thérapeutiques de l'obésité d'ici le début des années 2030 et $50,9 milliards pour l’arrêt du tabac d’ici 2030.
MIRA Pharmaceuticals (NASDAQ:MIRA) hat die Zustimmung der Aktionäre zur Übernahme von SKNY Pharmaceuticals bekannt gegeben, die einen kombinierten Enterprise Value von über $60 Millionen umfasst. Die Transaktion sieht vor, dass SKNY $5 Millionen in Vermögenswerten oder Bargeld an MIRA überlässt.
Die Akquisition bringt SKNY-1, einen neuartigen oralen Therapeutik-Kandidaten, der auf Adipositas und Raucherentwöhnung abzielt, in das Portfolio von MIRA. Präklinische Studien zeigten vielversprechende Ergebnisse mit einer bis zu 30%igen Gewichtsreduktion und einer Umkehr des Nikotinverlangens. Der einzigartige Wirkmechanismus zielt selektiv auf die Rezeptoren CB1 und CB2 sowie MAO-B ab und könnte eine verbesserte Sicherheit gegenüber früheren Behandlungen bieten.
Das kombinierte Unternehmen strebt Märkte an, die bis Anfang der 2030er Jahre auf $150 Milliarden für Adipositas-Therapien und auf $50,9 Milliarden für Raucherentwöhnung bis 2030 geschätzt werden.
MIRA Pharmaceuticals (NASDAQ:MIRA) أعلنت عن موافقة المساهمين على استحواذها على SKNY Pharmaceuticals، بقيمة مؤسسة مجمعة تفوق $60 مليون. تتضمن الصفقة مساهمة SKNY بـ $5 ملايين من الأصول أو النقد إلى MIRA.
تجلب الصفقة SKNY-1، مرشح علاجي فموي جديد يستهدف السمنة والإقلاع عن التدخين، إلى محفظة MIRA. أظهرت الدراسات قبل السريرية نتائج واعدة مع نقصان في الوزن يصل إلى 30% ونقض الرغبة في النيكوتين. آلية العمل الفريدة تستهدف مستقبلات CB1 وCB2 وMAO-B بشكل انتقائي، مما قد يوفر أماناً محتملاً محسناً مقارنة بالعلاجات السابقة.
تهدف الشركة المجمعة إلى استهداف أسواق من المتوقع أن تصل إلى $150 مليار لعلاجات السمنة بحلول أوائل الثلاثينيات من القرن الحالي و$50.9 مليار للإقلاع عن التدخين بحلول 2030.
MIRA Pharmaceuticals (NASDAQ:MIRA) 宣布股东已批准收购 SKNY Pharmaceuticals，合并企业价值超过 $60 百万。交易包括 SKNY 向 MIRA 贡献 $5 百万 的资产或现金。
此次收购将 SKNY-1 这一新型口服治疗候选药带入 MIRA 的产品线，目标为肥胖与戒烟。前临床研究显示结果颇为乐观，体重可减至多达 30%，尼古丁渴望也可逆转。该药物的独特机制能选择性地针对 CB1、CB2 受体和 MAO-B，可能相较早期治疗有更高安全性。
合并后公司瞄准的市场预计到 2030 年代初将达到 $1500 亿 的肥胖治疗市场，以及到 2030 年的戒烟市场约 $509 亿。
- Acquisition brings promising SKNY-1 drug candidate with dual indication potential for obesity and smoking cessation
- Preclinical results show significant 30% body weight reduction while preserving muscle mass
- Combined enterprise value of over $60 million post-merger
- SKNY to contribute $5 million in assets/cash, strengthening financial position
- Drug's unique mechanism potentially offers better safety profile than previous treatments
- Targeting two large growing markets: obesity ($150B by 2030s) and smoking cessation ($50.9B by 2030)
- Transaction still subject to closing conditions
- SKNY-1 is still in preclinical stage, requiring significant development before potential commercialization
- Previous CB1-targeting drugs faced psychiatric side effect challenges
- Share exchange structure may lead to dilution for existing MIRA shareholders
Insights
MIRA's acquisition of SKNY adds a promising obesity/addiction therapy with strong preclinical data, targeting multi-billion dollar markets.
This shareholder approval represents a significant strategic expansion for MIRA Pharmaceuticals. The acquisition brings SKNY-1 into MIRA's pipeline - a novel oral candidate with a differentiated mechanism targeting the endocannabinoid system that has shown impressive preclinical results: up to
What makes SKNY-1 particularly noteworthy is its selective pharmacology. By blocking β-arrestin signaling of CB1 receptors while preserving G-protein signaling, SKNY-1 aims to overcome the psychiatric side effects that derailed previous CB1-targeting obesity drugs like rimonabant. This approach could potentially deliver weight loss benefits without the mood destabilization that has plagued this drug class.
The
While still in preclinical stages with IND-enabling studies ahead, SKNY-1's dual-indication potential and oral delivery format could position it competitively in markets currently dominated by injectable GLP-1 therapies for obesity and various nicotine replacement therapies for smoking cessation. The acquisition represents a calculated risk in these high-value therapeutic areas where novel mechanisms are desperately needed.
SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to
MIAMI, FL / ACCESS Newswire / September 12, 2025 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapeutics for neurologic, neuropsychiatric, and metabolic disorders, today announced that its stockholders have approved the acquisition of SKNY Pharmaceuticals, Inc. ("SKNY") at the Company's 2025 Annual Meeting of Stockholders.
All proposals at the meeting were approved by shareholders, including the SKNY acquisition. The Company expects the transaction to close shortly, subject to customary closing conditions.
Transaction Terms and Valuation
Under the terms of the definitive agreement, the acquisition will be structured as a share exchange, with SKNY shareholders receiving shares of MIRA common stock in exchange for their SKNY shares.
At closing, SKNY shall contribute an amount of assets or cash (or a combination of the two) totaling
Independent third-party valuation analyses conducted by Moore Financial Consulting assigned an enterprise value of approximately
SKNY-1: A Differentiated Oral Approach to Obesity and Addiction
SKNY-1 is a next-generation oral drug candidate designed to target the endocannabinoid system with precision, modulating CB1 and CB2 receptors and MAO-B to address appetite, reward, and craving-without the psychiatric side effects that halted earlier CB1-targeting drugs.
Key preclinical results include:
Up to
30% body weight reduction in animal models, with preservation of muscle mass.Reversal of nicotine craving and high-calorie food cravings, supporting its potential as a dual-indication therapy.
Reversal of CB1-induced anxiety-like behavior in validated animal models, suggesting improved CNS safety compared with earlier agents.
Mechanistic studies conducted by Eurofins demonstrated that SKNY-1 selectively blocks β-arrestin signaling of CB1 receptors while sparing G-protein signaling, a design intended to reduce food intake and body weight without destabilizing mood.
"We believe SKNY-1 could be a best-in-class oral therapy for two of the leading causes of preventable death-obesity and nicotine addiction. Our shareholders' approval is a major milestone that positions us to close the SKNY acquisition and advance this program toward IND-enabling studies," said Erez Aminov, Chief Executive Officer of MIRA.
Market Opportunity
The global obesity therapeutics market is projected to surpass
$150 billion by the early 2030s (Reuters).The U.S. smoking cessation market is forecast to grow from
$28 billion in 2024 to approximately$50.9 billion by 2030 (Grand View Research).
By combining differentiated pharmacology, oral delivery, and dual efficacy across obesity and addiction, SKNY-1 may offer a compelling profile for these high-value, underserved markets.
Scientific Perspective
"SKNY-1 has a unique profile with biased CB1 signaling and unique CB2 profile, and our preclinical data now confirm it can reduce cravings, lower weight and metabolic parameters, and reverses CB1-agonist induced anxiety-addressing the very limitations that halted earlier drugs in this class," said Dr. Itzchak Angel, Chief Scientific Advisor at MIRA.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of MIRA's management related thereto contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any statements in this press release that are not historical facts may be deemed forward-looking. Any forward-looking statements in this press release are based on MIRA's current expectations, estimates, and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond MIRA's control) that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements, including related to MIRA's potential merger with SKNY Pharmaceuticals, Inc. These and other risks concerning MIRA's programs and operations are described in additional detail in the Annual Report on Form 10-K for the year ended December 31, 2024, and the Form 14A filed by MIRA on June 18, 2025, and other SEC filings, which are on file with the SEC at www.sec.gov and on MIRA's website at https://www.mirapharmaceuticals.com/investors/sec-filings. MIRA explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
Contact:
Helga Moya
info@mirapharma.com
(786) 432-9792
SOURCE: MIRA Pharmaceuticals
View the original press release on ACCESS Newswire
FAQ
What are the key terms of MIRA Pharmaceuticals' acquisition of SKNY Pharmaceuticals?
What are the main benefits of SKNY-1, MIRA's newly acquired drug candidate?
How large is the market opportunity for MIRA's SKNY-1 drug?
What makes SKNY-1 different from previous obesity and addiction treatments?
What stage of development is SKNY-1 currently in?
